Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05518474
Other study ID # homeproningpilot_21_069
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date October 15, 2021
Est. completion date February 1, 2023

Study information

Verified date May 2023
Source Unity Health Toronto
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The rapid development of safe and effective COVID-19 treatment is a global health priority. Numerous studies evaluating therapies for this disease are currently underway, but the majority of these are in hospitalized patients with severe illness. Consequently, there is an urgent need to identify therapies that prevent mild COVID-19 cases in the community from becoming more severe. "Proning" or lying face down in bed has been shown to improve breathing and oxygen levels in COVID-19 patients, reducing the need for breathing tubes and ventilators and increasing survival. The current study will investigate whether proning and repositioning (lying on one's side or sitting up) can prevent mild cases of COVID-19 from becoming more severe resulting in fewer hospitalizations and death. A randomized controlled trial will be used to reduce the risk of bias when testing this intervention. Unvaccinated or partially vaccinated adult patients with a positive COVID-19 test willing to participate and well enough to be treated outside the hospital will be randomly assigned to one of two groups: a home-proning intervention group with instructions and daily reminders to prone and reposition during the day and at night, and a standard care group. Our goal is to assess whether home-proning/repositioning leads to fewer hospitalizations and death when compared with standard care. We'll also compare recovery time, use of antibiotics and follow up emergency department visits between these two groups. The current pilot study will assess the feasibility of a larger investigation or "main trial", meaning it will be small scale test of methods and procedures to be used on a larger scale.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date February 1, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years 2. Positive SARS-CoV-2 PCR test 3. Presence of two or more of the following criteria: 1. Age>55 years 2. Fever by history or at presentation 3. Cough 4. Dyspnea/shortness of breath 5. Fatigue necessitating daytime bed rest 6. One or more of the following medical conditions: - Hypertension - Diabetes - Cardiovascular disease - Chronic lung disease - Chronic kidney disease - Obesity (BMI=30kg/m2) 7. Tachycardia > 110 bpm 8. Oxygen saturation <94% 9. One or more of the following laboratory abnormalities: - Lymphocytes <1500/microL - ESR > 100 mm/h - CRP > 10 mg/L - D-Dimer > 1000 ng/mL - LDH > 240 U/L 10. Bilateral infiltrates or ground glass opacities on chest x-ray or CT scan 4. Socially and medically fit for discharge 5. Access to a smartphone Exclusion Criteria: 1. Pregnancy >20/40 weeks 2. Body mass index (BMI) >40 kg/m2. 3. Skeletal deformities that interfere with proning 4. Developmental delay or cognitive impairment that would preclude patient cooperation 5. Other contraindications to proning including any of the following: recent abdominal surgery, active vomiting, acute intoxication. 6. Unlikely to adhere to the proning protocol according to the treating physician's judgment 7. Fully vaccinated for COVID-19

Study Design


Intervention

Other:
Self-proning
Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.

Locations

Country Name City State
Canada St. Joseph's Health Centre Toronto Ontario

Sponsors (2)

Lead Sponsor Collaborator
Unity Health Toronto Applied Health Research Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Feasibility outcome: successful recruitment Defined as >=50% of eligible participants agreeing to enrollment Through study completion, on average one year
Other Feasibility outcome: successful retention of trial participants, Defined as <10% attrition rate Up to 28 days
Other Feasibility outcome: adherence to the intervention Defined as self-proning and repositioning daily for >=75% of days of symptom duration. Adherence will be ascertained through daily survey of study participants. Up to 28 days
Primary Composite of hospitalization and all cause mortality The primary outcome is a composite of hospital admission and all-cause mortality. This will be ascertained using telephone follow up and deterministic record linkage performed by the Institute for Clinical Evaluative Sciences (ICES) using their Discharge Abstract Database (DAD). Up to 28 days post-randomization
Secondary Hospitalization Up to 28 days post-randomization
Secondary All cause mortality Up to 28 days post-randomization
Secondary Time to functional recovery in days Defined as: resolution of fever for 48 hours, significant symptom reduction and ability to perform most daily activities or return to work, if applicable, for two consecutive days. Up to 28 days post-randomization
Secondary Use of antibiotics for respiratory illness Up to 28 days post-randomization
Secondary Follow up emergency department assessment without hospital admission Number of subsequent emergency department visits by study participants that relate to the initial COVID-19 presentation but do not result in hospital admission Up to 28 days post-randomization
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure